<DOC>
	<DOCNO>NCT01558310</DOCNO>
	<brief_summary>This single site , randomize , placebo-controlled , cross-over trial sub-cutaneous injection placebo Stelara™ ( ustekinumab ) subject scalp psoriasis.The purpose study assess effectiveness Stelara™ ( ustekinumab ) treatment scalp psoriasis determine proportion subject clear almost clear scalp specific physician assessment . The study include approximately 30 subject .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness STELARA ™ ( USTEKINUMAB ) Treatment Scalp Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Capable give informed consent consent must obtain prior study related procedure . Be 18 year age old time consent ; may male female . Have diagnosis plaque psoriasis least 6 month prior administration study agent . Presence moderate severe psoriasis body scalp . At least 30 % scalp affect erythema , induration desquamation sPGA score great equal 4 . Be candidate phototherapy systemic treatment psoriasis . Women childbearing potential men must use adequate birth control measure ( eg abstinence , oral contraceptive , intrauterine device , barrier method spermicide , surgical sterilization ) must agree continue use measure become pregnant plan pregnancy 12 month receive last injection study agent . Be able adhere protocol requirement study visit schedule . Must agree receive live virus live bacterial vaccination trial 12 month last study injection . Must agree receive BCG vaccination trial 12 month last injection . Must avoid prolonged sun exposure avoid use tan booths ultraviolet light source study . Are consider eligible accord follow tuberculosis ( TB ) screen criterion : Have history latent active TB prior screen . An exception make subject currently receive treatment latent TB evidence active TB , history latent TB documentation complete appropriate treatment latent TB within 3 year prior first administration study agent . It responsibility investigator verify adequacy previous antituberculous treatment provide appropriate documentation . Have sign symptom suggestive active TB upon medical history and/or physical examination . Within 6 week prior first administration study agent , negative QuantiFERONTB Gold test result ( see Attachment # ) .Indeterminate result handle outlined Section # , Exclusion Criteria . Have chest radiograph ( posterioranterior lateral view ) , take within 3 month prior first administration study agent read qualified radiologist , evidence current , active TB old , inactive TB . Have screen laboratory test result within follow parameter : Hemoglobin &gt; 10g/dL White Blood Cells &gt; 3.5 x 109 /L Neutrophils &gt; 1.5 x 109 /L Platelets &gt; 100 X109 /L Serum Creatinine &lt; 1.5 mg/dL ( 133 micromol/L ) AST , ALT , alkaline phosphatase level must within 1.5 time upper limit normal range laboratory conduct test Subjects meeting follow criterion may enrol study : Currently nonplaque form psoriasis ( erythrodermic , guttate , pustular ) . Have current druginduced psoriasis . Presence skin condition ( include scalp ) psoriasis would interfere evaluation effect study agent . Are pregnant , nursing , plan pregnancy ( men woman ) enrol study . Have use therapeutic agent target reduce IL12 and/or IL23 , include limited ustekinumab ABT 874 . Have use investigational drug within previous 4 week 5 time halflife investigational agent , whatever longer . Have use investigational drug within previous 3 month 5 time halflife biological , whichever longer . Have ever receive natalizumab agent target alpha4integrin . Have receive phototherapy systemic medications/treatments could affect psoriasis sPGA/PASI evaluation ( include limit , oral injectable corticosteroid , retinoids,1,25 dihydroxy vitamin D3 analogue , psoralens , sulfasalazine , hydroxyurea , fumaric acid derivative ) within 4 week administration study agent . Have use topical mediations/treatments could affect psoriasis sPGA/PASI evaluation ( eg corticosteroid , anthralin , calcipotriene , topical vitamin D derivative , retinoids , tazarotene , methoxsalen , trimethylpsoralens ) within 2 week first administration study agent . Have use systemic immunosuppressant ( eg Methotrexate , azathioprine , cyclosporine,6thioguanine , mercaptopurine , mycophenolate , mofetil , hydroxyurea , tacrolimus ) within 4 week first administration study agent . Are currently receive lithium , antimalarial , intramuscular gold , receive lithium , antimalarial , intramuscular gold , receive lithium , antimalarial , intramuscular gold within 4 week first administration study agent . Have receive within 3 month prior first injection live virus bacterial vaccination . Subjects must agree receive live virus bacterial vaccination trial 12 month last study agent injection . Have BCG vaccination within 12 month screen . Subject must agree receive BCG vaccination trial 12 month last study agent injection . Have history chronic recurrent infectious disease , include limited chronic renal infection , chronic chest infection ( eg bronchiectasis ) , recurrent urinary tract infection ( recurrent pyelonephritis chronic nonremitting cystitis ) , open , drain , infected skin wound ulcer . Have serious infection ( eg sepsis , pneumonia , pyelonephritis ) hospitalize receive IV antibiotic infection 2 month prior screen Have history latent active granulomatous infection , include histoplasmosis coccidioidomycosis , prior screen . Have persistently indeterminate ( indeterminate repeat sample ) QuantiFERONTB Gold test result Have Bacille CalmetteGuérin ( BCG ) vaccination within 12 month screen . Have chest radiograph within 3 month prior first administration study agent show abnormality suggestive malignancy current active infection , include TB . Have nontuberculous mycobacterial infection opportunistic infection ( eg , cytomegalovirus , pneumocystosis , aspergillosis ) within 6 month prior screen . Known infected human immunodeficiency virus , hepatitis B , hepatitis C. Have current sign symptom severe , progressive , uncontrolled renal , hepatic , haematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease . Have transplant organ . Have know history lymphoproliferative disease , include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy /or splenomegaly . Have know malignancy history malignancy ( exception basal cell carcinoma , squamous cell carcinoma situ skin cervix treat evidence recurrence , squamous cell carcinoma skin treat evidence recurrence within 5 year prior first administration study agent ) . Have hospitalize past 3 year asthma , ever require intubation treatment asthma , currently require oral corticosteroid treatment asthma , require one short term ( &lt; 2 week ) course oral corticosteroid asthma within previous year . Have undergone allergy immunotherapy previously prevention anaphylactic reaction . Have show previous immediate hypersensitivity response , include anaphylaxis , immunoglobulin product ( eg plasma derive recombinant monoclonal antibody ) . Be know substance abuse ( drug alcohol ) problem within previous 12 month . Be participate another trial use investigational agent procedure participation trial . Use tar shampoo within 14 day first dose study drug . Use OTC shampoo scalp psoriasis allow study . Use topical corticosteroid topical agent treatment psoriasis scalp allow study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>